RESUMO
This is the third in the series of historical articles dealing with developments in clinical pathology. Bence Jones proteins are immunoglobulin light chains found in excessive quantities in urine in multiple myeloma and are believed to be one of the first tumour markers ever discovered . Dr Henry Bence Jones is credited with the discovery of this protein in 1847 that bears his name and he can also be regarded as the first chemical pathologist/clinical chemist. Since then, numerous advances and refinements have been made in the measurement and detection of urine light chain proteins which have resulted in the current sensitive serum free light chain assays used today.
Assuntos
Proteína de Bence Jones/história , Biomarcadores Tumorais/história , Neoplasias de Plasmócitos/história , Patologia Clínica/história , Proteína de Bence Jones/urina , Biomarcadores Tumorais/urina , Difusão de Inovações , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Neoplasias de Plasmócitos/diagnóstico , Neoplasias de Plasmócitos/urina , Valor Preditivo dos Testes , Urinálise/históriaRESUMO
Multiple Myeloma has been recognized since Ancient Times. The first well-documented case was reported in 1844 by Samuel Solly. The most commonly recognized case is that of Thomas Alexander McBean, a highly respectable tradesman from London in 1850. Mr. McBean excreted a large amount of protein that was described by Henry Bence Jones in the middle of the 19th century. Jones was a well-known physician and made many contributions to medicine. One of the best known cases of multiple myeloma was that of Dr. Loos that was reported by Otto Kahler. The recognition of plasma cells and subsequently their product, a monoclonal protein has been described in detail. The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide.
Assuntos
Mieloma Múltiplo/história , Corticosteroides/história , Corticosteroides/uso terapêutico , Alquilantes/história , Alquilantes/uso terapêutico , Proteína de Bence Jones/análise , Proteína de Bence Jones/história , Ácidos Borônicos/uso terapêutico , Bortezomib , História do Século XIX , História Antiga , Humanos , Lenalidomida , Melfalan/uso terapêutico , Mieloma Múltiplo/tratamento farmacológico , Paraproteinemias/história , Prednisona/uso terapêutico , Proteinúria/história , Pirazinas/uso terapêutico , Transplante de Células-Tronco , Talidomida/análogos & derivados , Talidomida/uso terapêutico , Uretana/uso terapêuticoRESUMO
In the 1980s, new methods of parallel peptide synthesis were used to make large libraries of peptides, which were then screened for binding to Bence-Jones dimers. Subsequent X-ray crystallography of the Bence-Jones proteins, which had been infiltrated with peptide ligand, was used to determine the structural correlate of the binding data. The mode of binding was found to be not predictable and insight was gained into the forces determining how the so-called mimotopes interacted with binding sites.